The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701.
 
Jeremy S. Abramson
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb/Celgene; Janssen; Kite, a Gilead company; Regeneron
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Alimera Sciences; AstraZeneca; BeiGene; Bluebird Bio; Bristol-Myers Squibb; C4 Therapeutics; Caribou Biosciences; Celgene; Cellectar; Century Therapeutics; EMD Serono; Epizyme; Genmab; Incyte; Interius Biotherapeutics; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Kymera; Lilly; MorphoSys; MorphoSys; MustangBio; Novartis; Ono Pharmaceutical; Roche/Genentech; Seagen; Takeda
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Cellectis (Inst); Merck (Inst); MustangBio (Inst); Regeneron (Inst); Seagen (Inst)
 
Susan Michelle Geyer
No Relationships to Disclose
 
Levi D Pederson
No Relationships to Disclose
 
Sharmila Giri
No Relationships to Disclose
 
Eric D. Hsi
No Relationships to Disclose
 
Richard F. Little
No Relationships to Disclose
 
Steven Gore
No Relationships to Disclose
 
Daniel J Landsburg
Consulting or Advisory Role - ADC Therapeutics; Epizyme; Incyte; Karyopharm Therapeutics; MorphoSys
Speakers' Bureau - Seagen
Research Funding - Calithera Biosciences; Curis (Inst)
Other Relationship - Karyopharm Therapeutics
 
Hua-Jay Jeffery Cherng
No Relationships to Disclose
 
Brad S. Kahl
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb; Genentech; Incyte; Janssen; Kite/Gilead; MEI Pharma; Roche; Seattle Genetics/Astellas; TG Therapeutics
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Genentech (Inst)
 
Neha Mehta-Shah
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Genentech/Roche; Janssen Oncology; Kyowa Hakko Kirin; Secura Bio
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo; Dizal Pharma (Inst); Genentech/Roche (Inst); Innate Pharma (Inst); Secura Bio (Inst); Verastem (Inst); Yingli Pharma (Inst)
 
Shira Dinner
No Relationships to Disclose
 
Jonathan W. Friedberg
Research Funding - Enterome (Inst)
Patents, Royalties, Other Intellectual Property - Patient on bone marrow microenvironment signals (I)
 
Nancy L. Bartlett
Consulting or Advisory Role - Foresight Diagnostics; Genmab/AbbVie (Inst); Kite, a Gilead company; Roche/Genentech
Research Funding - ADC Therapeutics (Inst); Autolus (Inst); Bristol-Myers Squibb/Celgene; Forty Seven (Inst); Janssen (Inst); Kite, a Gilead company; Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
John Paul Leonard
No Relationships to Disclose